score_bin	sensitive_predictive_implication	resistance_predictive_implication	prognostic_predictive_implication	feature_type	feature	alteration_type	alteration	tumor_f	total_coverage	exac_af	exac_common	clinvar	sensitive_score_bin	sensitive_therapy_name	sensitive_therapy_strategy	sensitive_therapy_type	sensitive_description	sensitive_citation	sensitive_url	resistance_score_bin	resistance_therapy_name	resistance_therapy_strategy	resistance_therapy_type	resistance_description	resistance_citation	resistance_url	prognostic_score_bin	favorable_prognosis	prognostic_description	prognostic_citation	prognostic_url	number_germline_mutations_in_gene	validation_total_coverage	validation_tumor_f	validation_detection_power	feature_display	preclinical_efficacy_observed	patient_id	tumor_sample_barcode	normal_sample_barcode
Putatively Actionable	Preclinical			Copy Number	CDKN2A	Deletion				0.0	0.0		Putatively Actionable	EPZ015666	PRMT5 inhibition	Targeted therapy	These deletions are typically codeleted with MTAP, which has enhanced dependency on PRMT5 for which there is an inhibitor in clincial development	Kryukov GV, Wilson FH, Ruth JR, et al. MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells. Science. 2016;351(6278):1214-8.	https://doi.org/10.1126/science.aad5214													0				CDKN2A Deletion		MEL-IPI_Pat138	MEL-IPI_Pat138-Tumor-SM-7A155	
Investigate Actionability	Clinical evidence	Clinical evidence		Somatic Variant	RET	Missense	p.E1006K	0.2394	71.0	0.0	0.0		Investigate Actionability	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict sensitivity to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137	Investigate Actionability	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict resistance to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137						0				RET p.E1006K (Missense)		MEL-IPI_Pat138	MEL-IPI_Pat138-Tumor-SM-7A155	MEL-IPI_Pat138-Normal-SM-5VWHX
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB3	Missense	p.P223S	0.201	209.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475													0				ERBB3 p.P223S (Missense)		MEL-IPI_Pat138	MEL-IPI_Pat138-Tumor-SM-7A155	MEL-IPI_Pat138-Normal-SM-5VWHX
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB3	Missense	p.R1089Q	0.2093	86.0	1.6e-05	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475													0				ERBB3 p.R1089Q (Missense)		MEL-IPI_Pat138	MEL-IPI_Pat138-Tumor-SM-7A155	MEL-IPI_Pat138-Normal-SM-5VWHX
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB2	Missense	p.P66L	0.1912	68.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475													0				ERBB2 p.P66L (Missense)		MEL-IPI_Pat138	MEL-IPI_Pat138-Tumor-SM-7A155	MEL-IPI_Pat138-Normal-SM-5VWHX
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB2	Missense	p.D982E	0.0469	128.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475													0				ERBB2 p.D982E (Missense)		MEL-IPI_Pat138	MEL-IPI_Pat138-Tumor-SM-7A155	MEL-IPI_Pat138-Normal-SM-5VWHX
Investigate Actionability	Clinical evidence			Somatic Variant	ERCC2	Missense	p.S322F	0.4444	9.0	0.0	0.0		Investigate Actionability	Cisplatin	Platinum-based chemotherapy	Chemotherapy	Somatic mutations that occured in ERCC2 were enriched in responders relative to nonresponsers in a cohort of patients with muscle-invasive urothelial carcinoma who received neoadjuvant cisplatin-based chemotherapy followed by cystectomy.	Liu D, Plimack ER, Hoffman-censits J, et al. Clinical Validation of Chemotherapy Response Biomarker ERCC2 in Muscle-Invasive Urothelial Bladder Carcinoma. JAMA Oncol. 2016;2(8):1094-6.	https://doi.org/10.1001/jamaoncol.2016.1056													0				ERCC2 p.S322F (Missense)	0.0	MEL-IPI_Pat138	MEL-IPI_Pat138-Tumor-SM-7A155	MEL-IPI_Pat138-Normal-SM-5VWHX
Investigate Actionability	Clinical evidence			Somatic Variant	ARAF	Missense	p.G163E	0.5217	92.0	0.0	0.0		Investigate Actionability	Sorafenib	RAF inhibition	Targeted therapy	Activating mutations in ARAF may predict sensitivity to sorafenib or other RAF inhibitors. Patient received 5 year response to sorafenib with ARAF S214C.	Imielinski M, Greulich H, Kaplan B, et al. Oncogenic and sorafenib-sensitive ARAF mutations in lung adenocarcinoma. J Clin Invest. 2014;124(4):1582-6.	https://doi.org/10.1172/JCI72763													0				ARAF p.G163E (Missense)	0.0	MEL-IPI_Pat138	MEL-IPI_Pat138-Tumor-SM-7A155	MEL-IPI_Pat138-Normal-SM-5VWHX
Investigate Actionability	Clinical evidence			Mutational Burden	High Mutational Burden								Investigate Actionability	Ipilimumab	CTLA-4 inhibition	Immunotherapy	In a study of malignant melanoma using a discovery cohort of 25 patients and a validation cohort of 39 patients, a significantly higher muational burden was seen in patients with a long-term clinical benefit vs. patients with minimal or no benefit to ipilimumab treatment.	Snyder A, Makarov V, Merghoub T, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med. 2014;371(23):2189-99.	https://doi.org/10.1056/NEJMoa1406498													0				 mutations per Mb		MEL-IPI_Pat138		
Investigate Actionability	Preclinical	Clinical evidence	Clinical trial	Somatic Variant	PTEN	Frameshift	p.K183fs	0.6333	270.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PTEN loss of function may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p	Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	PTEN loss may predict resistance to immune checkpoint blockade	George S, Miao D, Demetri GD, et al. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity. 2017;46(2):197-204.	https://doi.org/10.1016/j.immuni.2017.02.001	Investigate Actionability	0.0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310	0				PTEN p.K183fs (Frameshift)	1.0	MEL-IPI_Pat138	MEL-IPI_Pat138-Tumor-SM-7A155	MEL-IPI_Pat138-Normal-SM-5VWHX
Investigate Actionability	Preclinical	Clinical evidence	Clinical trial	Somatic Variant	PTEN	Frameshift	p.K183fs	0.5311	322.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PTEN loss of function may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p	Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	PTEN loss may predict resistance to immune checkpoint blockade	George S, Miao D, Demetri GD, et al. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity. 2017;46(2):197-204.	https://doi.org/10.1016/j.immuni.2017.02.001	Investigate Actionability	0.0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310	0				PTEN p.K183fs (Frameshift)	1.0	MEL-IPI_Pat138	MEL-IPI_Pat138-Tumor-SM-7A155	MEL-IPI_Pat138-Normal-SM-5VWHX
Investigate Actionability	Preclinical	Preclinical		Somatic Variant	ALK	Missense	p.E1526K	0.2368	380.0	0.0	0.0		Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846	Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846						0				ALK p.E1526K (Missense)		MEL-IPI_Pat138	MEL-IPI_Pat138-Tumor-SM-7A155	MEL-IPI_Pat138-Normal-SM-5VWHX
Investigate Actionability	Preclinical	Preclinical		Somatic Variant	ALK	Missense	p.Y1507C	0.18600000000000003	172.0	0.0	0.0		Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846	Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846						0				ALK p.Y1507C (Missense)		MEL-IPI_Pat138	MEL-IPI_Pat138-Tumor-SM-7A155	MEL-IPI_Pat138-Normal-SM-5VWHX
Investigate Actionability	Preclinical			Somatic Variant	FBXW7	Missense	p.G579E	0.0877	57.0	0.0	0.0		Investigate Actionability	Sirolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Breast cancer tumor cell lines harboring deletions or mutations in FBXW7 are particularly sensitive to rapamycin treatment, FBXW7 may be a biomarker for human cancers susceptible to treatment with inhibitors of the mTOR pathway.	Mao JH, Kim IJ, Wu D, et al. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science. 2008;321(5895):1499-502.	https://doi.org/10.1126/science.1162981													0				FBXW7 p.G579E (Missense)		MEL-IPI_Pat138	MEL-IPI_Pat138-Tumor-SM-7A155	MEL-IPI_Pat138-Normal-SM-5VWHX
Investigate Actionability	Preclinical			Somatic Variant	FBXW7	Missense	p.H382Y	0.2805	164.0	0.0	0.0		Investigate Actionability	Sirolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Breast cancer tumor cell lines harboring deletions or mutations in FBXW7 are particularly sensitive to rapamycin treatment, FBXW7 may be a biomarker for human cancers susceptible to treatment with inhibitors of the mTOR pathway.	Mao JH, Kim IJ, Wu D, et al. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science. 2008;321(5895):1499-502.	https://doi.org/10.1126/science.1162981													0				FBXW7 p.H382Y (Missense)		MEL-IPI_Pat138	MEL-IPI_Pat138-Tumor-SM-7A155	MEL-IPI_Pat138-Normal-SM-5VWHX
Investigate Actionability	Preclinical			Somatic Variant	MET	Missense	p.S653F	0.18899999999999997	291.0	0.0	0.0		Investigate Actionability	SU11274	MET inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to SU11274.	Seiwert TY, Jagadeeswaran R, Faoro L, et al. The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res. 2009;69(7):3021-31.	https://doi.org/10.1158/0008-5472.CAN-08-2881													0				MET p.S653F (Missense)	0.0	MEL-IPI_Pat138	MEL-IPI_Pat138-Tumor-SM-7A155	MEL-IPI_Pat138-Normal-SM-5VWHX
Investigate Actionability	Preclinical			Somatic Variant	ATM	Missense	p.L1606F	0.2029	138.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	HCT116 colorectal cancer cell lines are heterozygous for c.3380C>A and sensitive to PARP inhibition following shRNA depletion of ATM. Deletion of p53 enhances sensitivity.	Wang C, Jette N, Moussienko D, Bebb DG, Lees-Miller SP. ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib Translational Oncology. 2017; 10(2):190-196.	https://doi.org/10.1016/j.tranon.2017.01.007													0				ATM p.L1606F (Missense)	1.0	MEL-IPI_Pat138	MEL-IPI_Pat138-Tumor-SM-7A155	MEL-IPI_Pat138-Normal-SM-5VWHX
Investigate Actionability	Inferential		Clinical evidence	Somatic Variant	POLE	Missense	p.L1245F	0.0507	138.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients whose tumors contain DNA repair deficiencies may benefit from anti-PD-1 therapy. MMR deficient colorectal and noncolorectal cancer were enriched for partial response to Pembrolizumab in a cohort of 41 patients.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596								Investigate Actionability	0.0	A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.	Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325-32.	https://doi.org/10.1038/gim.2015.75	0				POLE p.L1245F (Missense)		MEL-IPI_Pat138	MEL-IPI_Pat138-Tumor-SM-7A155	MEL-IPI_Pat138-Normal-SM-5VWHX
Investigate Actionability		Clinical evidence		Somatic Variant	MAP2K2	Missense	p.E142K	0.2348	115.0	0.0	0.0									Investigate Actionability	Trametinib	MEK inhibition	Targeted therapy	MEK2 Q60P was observed in a patient's trametinib resistant tumor but not pretreatment tumor.	"Wagle, Nikhil, et al. ""MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition."" Cancer discovery 4.1 (2014): 61-68."	https://doi.org/10.1158/2159-8290.CD-13-0631						0				MAP2K2 p.E142K (Missense)		MEL-IPI_Pat138	MEL-IPI_Pat138-Tumor-SM-7A155	MEL-IPI_Pat138-Normal-SM-5VWHX
Investigate Actionability		Clinical evidence		Somatic Variant	MAP2K2	Missense	p.G132D	0.2692	104.0	0.0	0.0									Investigate Actionability	Trametinib	MEK inhibition	Targeted therapy	MEK2 Q60P was observed in a patient's trametinib resistant tumor but not pretreatment tumor.	"Wagle, Nikhil, et al. ""MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition."" Cancer discovery 4.1 (2014): 61-68."	https://doi.org/10.1158/2159-8290.CD-13-0631						0				MAP2K2 p.G132D (Missense)		MEL-IPI_Pat138	MEL-IPI_Pat138-Tumor-SM-7A155	MEL-IPI_Pat138-Normal-SM-5VWHX
Investigate Actionability			Guideline	Somatic Variant	SETBP1	Missense	p.G287E	0.0568	88.0	0.0	0.0																Investigate Actionability	0.0	Associated with disease progression. More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	0				SETBP1 p.G287E (Missense)		MEL-IPI_Pat138	MEL-IPI_Pat138-Tumor-SM-7A155	MEL-IPI_Pat138-Normal-SM-5VWHX
Investigate Actionability			Guideline	Somatic Variant	STAG2	Splice Site	p.Q15Q	0.0484	289.0	0.0	0.0																Investigate Actionability	0.0	NCCN guideline for Myelodysplastic Syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	0				STAG2 p.Q15Q (Splice Site)		MEL-IPI_Pat138	MEL-IPI_Pat138-Tumor-SM-7A155	MEL-IPI_Pat138-Normal-SM-5VWHX
Investigate Actionability			Inferential	Aneuploidy	Whole genome doubling																						Investigate Actionability	0.0	WGD was associated with adverse survival pan-cancer in patients with advanced disease and in cancers with heterogeneous clinical outcomes, even following the development of metastasis.	Bielski CM, Zehir A, Penson AV, et al. Genome doubling shapes the evolution and prognosis of advanced cancers Nat Genet. 2018; 50(8):1189-1195.	https://doi.org/10.1038/s41588-018-0165-1	0						MEL-IPI_Pat138		
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA1	Missense	p.N1272D	0.1286	451.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. 	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf. Revised November 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA1 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677						0				BRCA1 p.N1272D (Missense)	1.0	MEL-IPI_Pat138	MEL-IPI_Pat138-Tumor-SM-7A155	MEL-IPI_Pat138-Normal-SM-5VWHX
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA1	Missense	p.S1217F	0.0867	150.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. 	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf. Revised November 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA1 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677						0				BRCA1 p.S1217F (Missense)	1.0	MEL-IPI_Pat138	MEL-IPI_Pat138-Tumor-SM-7A155	MEL-IPI_Pat138-Normal-SM-5VWHX
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA1	Missense	p.A579T	0.0205	293.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. 	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf. Revised November 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA1 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677						0				BRCA1 p.A579T (Missense)	1.0	MEL-IPI_Pat138	MEL-IPI_Pat138-Tumor-SM-7A155	MEL-IPI_Pat138-Normal-SM-5VWHX
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	BRIP1	Missense	p.T1059I	0.0138	434.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1.0	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287	0				BRIP1 p.T1059I (Missense)	1.0	MEL-IPI_Pat138	MEL-IPI_Pat138-Tumor-SM-7A155	MEL-IPI_Pat138-Normal-SM-5VWHX
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	BRIP1	Splice Site	p.P210L	0.0364	165.0	2.5e-05	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1.0	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287	0				BRIP1 p.P210L (Splice Site)	1.0	MEL-IPI_Pat138	MEL-IPI_Pat138-Tumor-SM-7A155	MEL-IPI_Pat138-Normal-SM-5VWHX
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	BRIP1	Splice Site	p.D127D	0.0612	196.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1.0	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287	0				BRIP1 p.D127D (Splice Site)	1.0	MEL-IPI_Pat138	MEL-IPI_Pat138-Tumor-SM-7A155	MEL-IPI_Pat138-Normal-SM-5VWHX
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	CHEK2	Missense	p.S235L	0.0708	113.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1.0	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287	0				CHEK2 p.S235L (Missense)	0.0	MEL-IPI_Pat138	MEL-IPI_Pat138-Tumor-SM-7A155	MEL-IPI_Pat138-Normal-SM-5VWHX
Investigate Actionability	FDA-Approved			Somatic Variant	TSC2	Missense	p.L119F	0.3289	149.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Everolimus is indicated for the treatment of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex in adults and pediatric patients who are not candidates for curative surgical resection	Novartis Pharmaceuticals Corporation. Afinitor (everolimus) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf. Revised February 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf													0				TSC2 p.L119F (Missense)		MEL-IPI_Pat138	MEL-IPI_Pat138-Tumor-SM-7A155	MEL-IPI_Pat138-Normal-SM-5VWHX
Investigate Actionability	FDA-Approved			Somatic Variant	TSC2	Missense	p.A1171V	0.1333	165.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Everolimus is indicated for the treatment of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex in adults and pediatric patients who are not candidates for curative surgical resection	Novartis Pharmaceuticals Corporation. Afinitor (everolimus) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf. Revised February 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf													0				TSC2 p.A1171V (Missense)		MEL-IPI_Pat138	MEL-IPI_Pat138-Tumor-SM-7A155	MEL-IPI_Pat138-Normal-SM-5VWHX
Investigate Actionability	FDA-Approved			Somatic Variant	CDK12	Missense	p.E157K	0.1088	147.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf													0				CDK12 p.E157K (Missense)	0.0	MEL-IPI_Pat138	MEL-IPI_Pat138-Tumor-SM-7A155	MEL-IPI_Pat138-Normal-SM-5VWHX
Investigate Actionability	FDA-Approved			Somatic Variant	CDK12	Missense	p.S257N	0.0269	446.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf													0				CDK12 p.S257N (Missense)	0.0	MEL-IPI_Pat138	MEL-IPI_Pat138-Tumor-SM-7A155	MEL-IPI_Pat138-Normal-SM-5VWHX
Investigate Actionability	FDA-Approved			Somatic Variant	CDK12	Splice Site	p.G750E	0.1591	132.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf													0				CDK12 p.G750E (Splice Site)	0.0	MEL-IPI_Pat138	MEL-IPI_Pat138-Tumor-SM-7A155	MEL-IPI_Pat138-Normal-SM-5VWHX
Investigate Actionability	Clinical evidence	Clinical evidence		Somatic Variant	BRCA2	Missense	p.T1505I	0.0684	117.0	0.0	0.0		Investigate Actionability	Nivolumab + Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Responders were enriched for mutation in BRCA2 mutations, mostly nonsense mutations. 6 of 21 responders had BRCA2 vs. 1 of 17 nonresponders.	Hugo W, Zaretsky JM, Sun L, et al. Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma Cell. 2016; 165(1):35-44.	https://doi.org/10.1016/j.cell.2016.02.065	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677						0				BRCA2 p.T1505I (Missense)		MEL-IPI_Pat138	MEL-IPI_Pat138-Tumor-SM-7A155	MEL-IPI_Pat138-Normal-SM-5VWHX
Investigate Actionability	Clinical evidence	Clinical evidence		Somatic Variant	BRCA2	Missense	p.P1702S	0.1616	99.0	3.3e-05	0.0		Investigate Actionability	Nivolumab + Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Responders were enriched for mutation in BRCA2 mutations, mostly nonsense mutations. 6 of 21 responders had BRCA2 vs. 1 of 17 nonresponders.	Hugo W, Zaretsky JM, Sun L, et al. Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma Cell. 2016; 165(1):35-44.	https://doi.org/10.1016/j.cell.2016.02.065	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677						0				BRCA2 p.P1702S (Missense)		MEL-IPI_Pat138	MEL-IPI_Pat138-Tumor-SM-7A155	MEL-IPI_Pat138-Normal-SM-5VWHX
Investigate Actionability	Clinical evidence			Somatic Variant	MSH2	Missense	p.G221R	0.1949	118.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596													0				MSH2 p.G221R (Missense)		MEL-IPI_Pat138	MEL-IPI_Pat138-Tumor-SM-7A155	MEL-IPI_Pat138-Normal-SM-5VWHX
Investigate Actionability	Clinical evidence			Somatic Variant	MSH2	Missense	p.E489K	0.0424	165.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596													0				MSH2 p.E489K (Missense)		MEL-IPI_Pat138	MEL-IPI_Pat138-Tumor-SM-7A155	MEL-IPI_Pat138-Normal-SM-5VWHX
Investigate Actionability	Clinical evidence			Somatic Variant	MSH6	Splice Site		0.1954	87.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596													0				MSH6  (Splice Site)		MEL-IPI_Pat138	MEL-IPI_Pat138-Tumor-SM-7A155	MEL-IPI_Pat138-Normal-SM-5VWHX
Investigate Actionability	Clinical evidence			Somatic Variant	MSH6	Missense	p.T1219I	0.2098	143.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596													0				MSH6 p.T1219I (Missense)		MEL-IPI_Pat138	MEL-IPI_Pat138-Tumor-SM-7A155	MEL-IPI_Pat138-Normal-SM-5VWHX
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Missense	p.S1386N	0.2203	177.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951													0				PBRM1 p.S1386N (Missense)		MEL-IPI_Pat138	MEL-IPI_Pat138-Tumor-SM-7A155	MEL-IPI_Pat138-Normal-SM-5VWHX
Investigate Actionability	Clinical evidence			Somatic Variant	MLH3	Missense	p.R797C	0.0306	327.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596													0				MLH3 p.R797C (Missense)		MEL-IPI_Pat138	MEL-IPI_Pat138-Tumor-SM-7A155	MEL-IPI_Pat138-Normal-SM-5VWHX
Investigate Actionability	Clinical evidence			Somatic Variant	MLH3	Missense	p.D707N	0.1946	370.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596													0				MLH3 p.D707N (Missense)		MEL-IPI_Pat138	MEL-IPI_Pat138-Tumor-SM-7A155	MEL-IPI_Pat138-Normal-SM-5VWHX
Investigate Actionability	Clinical evidence			Somatic Variant	MLH3	Missense	p.G23S	0.040999999999999995	122.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596													0				MLH3 p.G23S (Missense)		MEL-IPI_Pat138	MEL-IPI_Pat138-Tumor-SM-7A155	MEL-IPI_Pat138-Normal-SM-5VWHX
Investigate Actionability	Clinical evidence			Somatic Variant	FLCN	Missense	p.D33N	0.1184	76.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Loss of function mutations in TSC1, TSC2, or FLCN may predict sensitivity to mTOR inhibition	Iyer G, Hanrahan AJ, Milowsky MI, et al. Genome sequencing identifies a basis for everolimus sensitivity. Science. 2012;338(6104):221.	https://doi.org/10.1126/science.1226344													0				FLCN p.D33N (Missense)		MEL-IPI_Pat138	MEL-IPI_Pat138-Tumor-SM-7A155	MEL-IPI_Pat138-Normal-SM-5VWHX
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Missense	p.P198L	0.2917	24.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0.0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744	0				ARID1A p.P198L (Missense)		MEL-IPI_Pat138	MEL-IPI_Pat138-Tumor-SM-7A155	MEL-IPI_Pat138-Normal-SM-5VWHX
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Missense	p.S593F	0.1925	187.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0.0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744	0				ARID1A p.S593F (Missense)		MEL-IPI_Pat138	MEL-IPI_Pat138-Tumor-SM-7A155	MEL-IPI_Pat138-Normal-SM-5VWHX
Investigate Actionability	Preclinical			Somatic Variant	PIK3CB	Missense	p.Y618H	0.2268	194.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PIK3CB mutations may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p													0				PIK3CB p.Y618H (Missense)	0.0	MEL-IPI_Pat138	MEL-IPI_Pat138-Tumor-SM-7A155	MEL-IPI_Pat138-Normal-SM-5VWHX
Investigate Actionability	Preclinical			Copy Number	FGFR2	Deletion				0.0	0.0		Investigate Actionability	Infigratinib	FGFR inhibition	Targeted therapy	A study of 32 Cancer Cell Line Encyclopedia cell lines demonstrating FGFR1 and FGFR2 amplification demonstrated sensitivity to Infigratinib.	Guagnano V, Kauffmann A, Wohrle S, et al. FGFR genetic alterations predict for sensitivity to NVP-BGJ398, a selective pan-FGFR inhibitor. Cancer Discov. 2012;2(12):1118-33.	https://doi.org/10.1158/2159-8290.CD-12-0210													0				FGFR2 Deletion		MEL-IPI_Pat138	MEL-IPI_Pat138-Tumor-SM-7A155	
Investigate Actionability	Inferential		Clinical evidence	Somatic Variant	POLD1	Splice Site	p.G106S	0.19399999999999998	67.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients whose tumors contain DNA repair deficiencies may benefit from anti-PD-1 therapy. MMR deficient colorectal and noncolorectal cancer were enriched for partial response to Pembrolizumab in a cohort of 41 patients.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596								Investigate Actionability	0.0	A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.	Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325-32.	https://doi.org/10.1038/gim.2015.75	0				POLD1 p.G106S (Splice Site)		MEL-IPI_Pat138	MEL-IPI_Pat138-Tumor-SM-7A155	MEL-IPI_Pat138-Normal-SM-5VWHX
Investigate Actionability		Clinical evidence		Somatic Variant	BCR	Missense	p.S222N	0.2796	93.0	0.0	0.0									Investigate Actionability	Imatinib	BCR-ABL inhibition	Targeted therapy	Secondary mutations in BCR-ABL may suggest resistance to imatinib in CML.	Soverini S, Hochhaus A, Nicolini FE, Gruber F, Lange T, Saglio G, et al. (2011) Bcr-Abl kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inihibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood: blood-2010-2012-326405	https://doi.org/10.1182/blood-2010-12-326405						0				BCR p.S222N (Missense)		MEL-IPI_Pat138	MEL-IPI_Pat138-Tumor-SM-7A155	MEL-IPI_Pat138-Normal-SM-5VWHX
Investigate Actionability		Preclinical		Somatic Variant	NFE2L2	Missense	p.S236F	0.05	180.0	0.0	0.0									Investigate Actionability	Radiation therapy	Radiation	Radiation therapy	In a study of survival after radiation in lung squamous cancer cell lines, NFE2L2 conferred radiation resistance.	Abazeed ME, Adams DJ, Hurov KE, et al. Integrative Radiogenomic Profiling of Squamous Cell Lung Cancer Cancer Research. 2013; 73(20):6289-6298.	https://doi.org/10.1158/0008-5472.can-13-1616						0				NFE2L2 p.S236F (Missense)		MEL-IPI_Pat138	MEL-IPI_Pat138-Tumor-SM-7A155	MEL-IPI_Pat138-Normal-SM-5VWHX
Investigate Actionability		Preclinical		Somatic Variant	NFE2L2	Missense	p.P210S	0.22	150.0	0.00023199999999999997	0.0									Investigate Actionability	Radiation therapy	Radiation	Radiation therapy	In a study of survival after radiation in lung squamous cancer cell lines, NFE2L2 conferred radiation resistance.	Abazeed ME, Adams DJ, Hurov KE, et al. Integrative Radiogenomic Profiling of Squamous Cell Lung Cancer Cancer Research. 2013; 73(20):6289-6298.	https://doi.org/10.1158/0008-5472.can-13-1616						0				NFE2L2 p.P210S (Missense)		MEL-IPI_Pat138	MEL-IPI_Pat138-Tumor-SM-7A155	MEL-IPI_Pat138-Normal-SM-5VWHX
Investigate Actionability			Guideline	Somatic Variant	PRPF8	Missense	p.A2201T	0.0753	93.0	0.0	0.0																Investigate Actionability	0.0		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	0				PRPF8 p.A2201T (Missense)		MEL-IPI_Pat138	MEL-IPI_Pat138-Tumor-SM-7A155	MEL-IPI_Pat138-Normal-SM-5VWHX
Investigate Actionability			Guideline	Somatic Variant	ASXL1	Missense	p.S79N	0.1685	267.0	0.0	0.0																Investigate Actionability	0.0	Most frequent in Chronic Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	0				ASXL1 p.S79N (Missense)		MEL-IPI_Pat138	MEL-IPI_Pat138-Tumor-SM-7A155	MEL-IPI_Pat138-Normal-SM-5VWHX
Investigate Actionability			Guideline	Somatic Variant	RUNX1	Missense	p.L321F	0.2317	164.0	0.0	0.0																Investigate Actionability	0.0	May be familial in rare cases.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	0				RUNX1 p.L321F (Missense)		MEL-IPI_Pat138	MEL-IPI_Pat138-Tumor-SM-7A155	MEL-IPI_Pat138-Normal-SM-5VWHX
Investigate Actionability			Guideline	Somatic Variant	ZRSR2	Splice Site		0.0317	189.0	0.0	0.0																Investigate Actionability	0.0	NCCN guideline for Myelodysplastic Syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	0				ZRSR2  (Splice Site)		MEL-IPI_Pat138	MEL-IPI_Pat138-Tumor-SM-7A155	MEL-IPI_Pat138-Normal-SM-5VWHX
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.D299N	0.191	178.0	0.0	0.0																Investigate Actionability	1.0	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324	0				CTNNB1 p.D299N (Missense)		MEL-IPI_Pat138	MEL-IPI_Pat138-Tumor-SM-7A155	MEL-IPI_Pat138-Normal-SM-5VWHX
Investigate Actionability			Clinical evidence	Somatic Variant	BLM	Missense	p.G1011E	0.2014	139.0	0.0	0.0																Investigate Actionability	0.0	BLM may indicate a predisposition for early onset of colorectal cancer, although with a low-moderate penetrance.	De voer RM, Hahn MM, Mensenkamp AR, et al. Deleterious Germline BLM Mutations and the Risk for Early-onset Colorectal Cancer. Sci Rep. 2015;5:14060.	https://doi.org/10.1038/srep14060	0				BLM p.G1011E (Missense)		MEL-IPI_Pat138	MEL-IPI_Pat138-Tumor-SM-7A155	MEL-IPI_Pat138-Normal-SM-5VWHX
Biologically Relevant				Somatic Variant	EML4	Missense	p.P202S	0.1523	151.0	0.0	0.0																					0				EML4 p.P202S (Missense)		MEL-IPI_Pat138	MEL-IPI_Pat138-Tumor-SM-7A155	MEL-IPI_Pat138-Normal-SM-5VWHX
Biologically Relevant				Somatic Variant	MLH1	Missense	p.S179F	0.1477	176.0	0.0	0.0																					0				MLH1 p.S179F (Missense)		MEL-IPI_Pat138	MEL-IPI_Pat138-Tumor-SM-7A155	MEL-IPI_Pat138-Normal-SM-5VWHX
Biologically Relevant				Somatic Variant	TACC3	Missense	p.P417S	0.2263	137.0	0.0	0.0																					0				TACC3 p.P417S (Missense)		MEL-IPI_Pat138	MEL-IPI_Pat138-Tumor-SM-7A155	MEL-IPI_Pat138-Normal-SM-5VWHX
Biologically Relevant				Somatic Variant	TACC3	Splice Site	p.V531I	0.0822	73.0	0.0	0.0																					0				TACC3 p.V531I (Splice Site)		MEL-IPI_Pat138	MEL-IPI_Pat138-Tumor-SM-7A155	MEL-IPI_Pat138-Normal-SM-5VWHX
Biologically Relevant				Somatic Variant	ROS1	Missense	p.A1036T	0.0366	164.0	0.0	0.0																					0				ROS1 p.A1036T (Missense)		MEL-IPI_Pat138	MEL-IPI_Pat138-Tumor-SM-7A155	MEL-IPI_Pat138-Normal-SM-5VWHX
Biologically Relevant				Somatic Variant	ROS1	Missense	p.R187T	0.1603	156.0	0.0	0.0																					0				ROS1 p.R187T (Missense)		MEL-IPI_Pat138	MEL-IPI_Pat138-Tumor-SM-7A155	MEL-IPI_Pat138-Normal-SM-5VWHX
Biologically Relevant				Somatic Variant	PMS2	Missense	p.P566S	0.2582	364.0	0.0	0.0																					0				PMS2 p.P566S (Missense)		MEL-IPI_Pat138	MEL-IPI_Pat138-Tumor-SM-7A155	MEL-IPI_Pat138-Normal-SM-5VWHX
Biologically Relevant				Somatic Variant	PMS2	Nonsense	p.Q275*	0.03	233.0	8e-06	0.0																					0				PMS2 p.Q275* (Nonsense)		MEL-IPI_Pat138	MEL-IPI_Pat138-Tumor-SM-7A155	MEL-IPI_Pat138-Normal-SM-5VWHX
Biologically Relevant				Somatic Variant	POT1	Missense	p.P537L	0.2063	126.0	8e-06	0.0																					0				POT1 p.P537L (Missense)		MEL-IPI_Pat138	MEL-IPI_Pat138-Tumor-SM-7A155	MEL-IPI_Pat138-Normal-SM-5VWHX
Biologically Relevant				Somatic Variant	MDM2	Missense	p.E398K	0.1053	266.0	0.0	0.0																					0				MDM2 p.E398K (Missense)		MEL-IPI_Pat138	MEL-IPI_Pat138-Tumor-SM-7A155	MEL-IPI_Pat138-Normal-SM-5VWHX
Biologically Relevant				Somatic Variant	POLE2	Missense	p.T135I	0.0273	843.0	0.0	0.0																					0				POLE2 p.T135I (Missense)		MEL-IPI_Pat138	MEL-IPI_Pat138-Tumor-SM-7A155	MEL-IPI_Pat138-Normal-SM-5VWHX
Biologically Relevant				Somatic Variant	NF1	Missense	p.L1340F	0.0167	420.0	0.0	0.0																					0				NF1 p.L1340F (Missense)		MEL-IPI_Pat138	MEL-IPI_Pat138-Tumor-SM-7A155	MEL-IPI_Pat138-Normal-SM-5VWHX
Biologically Relevant				Somatic Variant	COL1A1	Splice Site	p.G1272E	0.0431	116.0	0.0	0.0																					0				COL1A1 p.G1272E (Splice Site)		MEL-IPI_Pat138	MEL-IPI_Pat138-Tumor-SM-7A155	MEL-IPI_Pat138-Normal-SM-5VWHX
Biologically Relevant				Somatic Variant	COL1A1	Missense	p.P978S	0.225	40.0	0.00014	0.0																					0				COL1A1 p.P978S (Missense)		MEL-IPI_Pat138	MEL-IPI_Pat138-Tumor-SM-7A155	MEL-IPI_Pat138-Normal-SM-5VWHX
Biologically Relevant				Somatic Variant	COL1A1	Missense	p.P376S	0.1562	160.0	0.0	0.0																					0				COL1A1 p.P376S (Missense)		MEL-IPI_Pat138	MEL-IPI_Pat138-Tumor-SM-7A155	MEL-IPI_Pat138-Normal-SM-5VWHX
Biologically Relevant				Somatic Variant	KEAP1	Missense	p.S431F	0.25	48.0	0.0	0.0																					0				KEAP1 p.S431F (Missense)		MEL-IPI_Pat138	MEL-IPI_Pat138-Tumor-SM-7A155	MEL-IPI_Pat138-Normal-SM-5VWHX
Biologically Relevant				Somatic Variant	CCNE1	Missense	p.N326S	0.0921	152.0	0.0	0.0																					0				CCNE1 p.N326S (Missense)		MEL-IPI_Pat138	MEL-IPI_Pat138-Tumor-SM-7A155	MEL-IPI_Pat138-Normal-SM-5VWHX
Biologically Relevant				Somatic Variant	TPX2	Missense	p.A85T	0.0211	237.0	0.0	0.0																					0				TPX2 p.A85T (Missense)		MEL-IPI_Pat138	MEL-IPI_Pat138-Tumor-SM-7A155	MEL-IPI_Pat138-Normal-SM-5VWHX
Biologically Relevant				Somatic Variant	ERG	Nonsense	p.W152*	0.2857	91.0	0.0	0.0																					0				ERG p.W152* (Nonsense)		MEL-IPI_Pat138	MEL-IPI_Pat138-Tumor-SM-7A155	MEL-IPI_Pat138-Normal-SM-5VWHX
Biologically Relevant				Copy Number	BRCA1	Amplification				0.0	0.0																					0				BRCA1 Amplification		MEL-IPI_Pat138	MEL-IPI_Pat138-Tumor-SM-7A155	
Biologically Relevant				Copy Number	EZH2	Deletion				0.0	0.0																					0				EZH2 Deletion		MEL-IPI_Pat138	MEL-IPI_Pat138-Tumor-SM-7A155	
Biologically Relevant				Copy Number	BLM	Deletion				0.0	0.0																					0				BLM Deletion		MEL-IPI_Pat138	MEL-IPI_Pat138-Tumor-SM-7A155	
Biologically Relevant				Copy Number	ABL1	Deletion				0.0	0.0																					0				ABL1 Deletion		MEL-IPI_Pat138	MEL-IPI_Pat138-Tumor-SM-7A155	
Biologically Relevant				Microsatellite Stability	Supporting variants		nan, DOCK3 p.G942S (Splice Site), PMS2 p.Q275* (Nonsense), PRDM2 p.703_704insP (Insertion)																									0				Supporting variants: nan, DOCK3 p.G942S (Splice Site), PMS2 p.Q275* (Nonsense), PRDM2 p.703_704insP (Insertion)		MEL-IPI_Pat138		
Biologically Relevant				Mutational Signature	COSMIC Signature 11	version 2	0.926																									0				COSMIC Signature (version 2) 11 (93%)		MEL-IPI_Pat138		
